Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nuscale Power Corporation (SMR) vs Viatris Inc (VTRS) Price & Performance

Nuscale Power CorporationTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Nuscale Power Corporation vs Viatris Inc — how do they compare? Nuscale Power Corporation trades at $10.83 (market cap $4.59B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is far larger — about 4.2× Nuscale Power Corporation's market cap, and Viatris Inc pays a 2.89% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.

SMRVTRS
Market Cap
$4.59B$19.09B
Sector
UtilitiesHealth
52-Week High
$53.43$17.86
52-Week Low
$7.59$9.49
Enterprise Value
$3.52B$31.21B
Dividend Yield
2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nuscale Power Corporation

SMR stock surged 15.32% to $11.18, showing strong bullish momentum with technical indicators supporting the uptrend. The company maintains a substantial cash position of $1.9 billion despite significant operating losses and negative profit margins. Recent news highlights NuScale's positioning in the nuclear energy sector, particularly for AI power demands, though the company remains years away from commercial deployment.

The outlook remains speculative with Wall Street divided - 50% of analysts recommend Buy with a $11.25 consensus target. Key risks include cash burn acceleration, lack of firm commercial contracts, and execution challenges in bringing small modular reactors to market. The stock offers high-risk/high-reward potential for investors betting on nuclear energy adoption.

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nuscale Power Corporation

NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.

Read more on SMR

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS